Precigen, Inc. (PGEN)

7.10 -0.04 (-0.56%) USD  |  NASDAQ  |  Sep 04, 16:00
7.11 +0.01 (+0.14%) After-Hours: 20:00
More

Precigen SG&A Expense (TTM) : 84.93M for June 30, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for PGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 84.93M
March 31, 2026 78.82M
December 31, 2025 70.13M
September 30, 2025 63.48M
June 30, 2025 49.33M
March 31, 2025 43.50M
December 31, 2024 41.29M
September 30, 2024 40.56M
June 30, 2024 39.92M
March 31, 2024 38.93M
December 31, 2023 40.42M
September 30, 2023 41.66M
June 30, 2023 42.60M
March 31, 2023 45.96M
December 31, 2022 48.01M
September 30, 2022 48.29M
June 30, 2022 49.13M
March 31, 2022 51.42M
December 31, 2021 56.43M
September 30, 2021 72.28M
June 30, 2021 83.61M
March 31, 2021 86.53M
December 31, 2020 89.31M
September 30, 2020 87.81M
June 30, 2020 87.69M
Date Value
March 31, 2020 89.07M
December 31, 2019 98.63M
September 30, 2019 94.58M
June 30, 2019 111.10M
March 31, 2019 126.27M
December 31, 2018 134.96M
September 30, 2018 145.72M
June 30, 2018 146.29M
March 31, 2018 150.70M
December 31, 2017 146.10M
September 30, 2017 148.62M
June 30, 2017 143.16M
March 31, 2017 134.58M
December 31, 2016 142.32M
September 30, 2016 141.69M
June 30, 2016 130.90M
March 31, 2016 124.31M
December 31, 2015 109.06M
September 30, 2015 94.10M
June 30, 2015 85.93M
March 31, 2015 77.65M
December 31, 2014 63.66M
September 30, 2014 56.18M
June 30, 2014 48.73M
March 31, 2014 40.77M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Anika Therapeutics, Inc. 52.67M
Geron Corp. 154.96M
Neurocrine Biosciences, Inc. 1.352B
Aldeyra Therapeutics, Inc. 8.438M
Elicio Therapeutics, Inc. 14.23M